DRUGapproved
Trastuzumab Deruxtecan
Mechanism
For HER2+ solid tumors. HERB trial in biliary cancer.
Related claims (1)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| drug efficacy | Trastuzumab deruxtecan and zanidatamab showed efficacy in patients with HER2 overexpression/amplification (clinical trial result) | 80% | 41060610 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.